CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
Clinical safety rating: safe
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation.
| Metabolism | Primarily hepatic via CYP3A4; metabolites include clindamycin sulfoxide and N-demethylclindamycin. |
| Excretion | Approximately 10% of administered dose excreted renally as active drug; significant biliary/fecal elimination (about 40% as active drug and metabolites) via enterohepatic circulation. |
| Half-life | Terminal elimination half-life is 2.4–3.0 hours in adults with normal hepatic and renal function; prolonged in severe hepatic impairment (up to 8–10 hours) and in neonates (8–20 hours). |
| Protein binding | 93–96% bound primarily to albumin. |
| Volume of Distribution | 0.6–1.2 L/kg (total body water); extensive distribution to most tissues except CNS (penetrates poorly into CSF even with inflamed meninges). |
| Bioavailability | Oral: ~87–90% (fasting); IM: ~87–100% (complete). Topical: minimal systemic absorption (<5% with intact skin). |
| Onset of Action | IV: Rapid, within minutes for antibacterial effect. IM: 1–3 hours to reach peak serum concentrations. Topical: 2–4 weeks for clinical improvement in acne. Oral: 1–2 hours. |
| Duration of Action | IV/IM: Serum levels above MIC for 6–8 hours with typical dosing intervals. Topical: After discontinuation, effects persist for weeks due to suppression of Cutibacterium acnes. |
| Molecular Weight | 461.4 Da (parent drug; clindamycin phosphate: 504.96 Da, but active moiety is clindamycin base) |
600-900 mg IV every 8 hours, or 900 mg IV every 12 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR ≥10 mL/min; for GFR <10 mL/min and anuric patients, give full dose every 8-12 hours or consider reducing dose by 50%. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment (Child-Pugh C) and monitor liver function. |
| Pediatric use | Neonates: 15-20 mg/kg/day IV divided every 6-8 hours; Infants and children: 20-40 mg/kg/day IV divided every 6-8 hours, up to 40 mg/kg/day for severe infections. |
| Geriatric use | No specific dose adjustment; monitor renal function and for adverse effects due to age-related decline in renal clearance. |
| 1st trimester | Generally considered safe; no evidence of fetal harm in animal studies or human data. Crosses placenta but no increased risk of congenital anomalies. |
| 2nd trimester | Safe for use; no known fetal risks. |
| 3rd trimester | Safe for use; no known fetal risks. |
Clinical note
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
| FDA category | Human |
| Placental transfer | Clindamycin crosses the placenta with cord blood levels approximately 50% of maternal serum levels. Fetal exposure is significant but not associated with teratogenicity. |
| Breastfeeding |
■ FDA Black Box Warning
Can cause severe and sometimes fatal colitis, including pseudomembranous colitis, due to Clostridioides difficile overgrowth.
| Common Effects | Diarrhea (including C. difficile) |
| Serious Effects |
Hypersensitivity to clindamycin or lincomycinHistory of antibiotic-associated colitis (e.g., C. difficile infection)Preterm infants (benzyl alcohol in some formulations may cause gasping syndrome; this formulation contains dextrose, not benzyl alcohol, but caution)
| Precautions | Monitor for antibiotic-associated colitis; use with caution in patients with gastrointestinal disease, hepatic impairment, and history of asthma or allergies. |
| Food/Dietary | No clinically significant food interactions. Administer without regard to meals. |
Loading safety data…
| Clindamycin is excreted into breast milk in small amounts. Although adverse effects in nursing infants are rare, caution is advised due to potential for gastrointestinal disturbances and altered infant gut flora. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Clindamycin is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies, but adequate human studies in pregnant women are lacking. Use only if clearly needed, especially in the first trimester. There is a potential risk of pseudomembranous colitis in the neonate if administered near term. |
| Fetal Monitoring | Monitor maternal liver function, renal function, and complete blood count periodically, especially with prolonged therapy. Observe for signs of pseudomembranous colitis. For neonate, monitor for diarrhea, thrush, or signs of gastrointestinal disturbance. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data insufficient to determine impact on fertility. |
| Clinical Pearls | Clindamycin phosphate in D5W is an IV formulation; avoid IM use. Monitor for pseudomembranous colitis (C. diff) due to high risk. Rapid infusion may cause hypotension; administer over at least 10-60 minutes. Contraindicated in patients with history of colitis. May cause neuromuscular blockade; use caution with neuromuscular blocking agents. |
| Patient Advice | Report any severe diarrhea, abdominal cramps, or bloody stools immediately. · Complete the full course of therapy even if you feel better. · Avoid alcohol during treatment and for 48 hours after completion. · Inform your doctor if you have a history of colitis, kidney disease, or allergies. |